Wiping up finger paint and tackling juice spills is a routine every parent has down pat. Yet they may find themselves playing hide-and-seek with the invisible things little hands leave behind—like bacteria and viruses. Germs stick to all types of surfaces, and kids spread them to more places than you can imagine.
To track down where germs linger, The Clorox Company and global public health organization NSF International conducted a study in homes of families with young children. Researchers analyzed 100 samples from five commonly-touched surfaces, and found bacteria or viruses on all five of the surfaces tested, from the kitchen to the common area to the bathroom, with the bathroom sink being one of the surfaces with the most germs. In fact, the study results found that four times as many households had bathroom sinks that were germier than kitchen countertops.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7359251-clorox-and-nsf-study-shows-which-surfaces-have-most-germs-in-homes-with-kids
New findings from the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project (PCGP) have helped identify the mechanism that makes the childhood eye tumor retinoblastoma so aggressive. The discovery explains why the tumor develops so rapidly while other cancers can take years or even decades to form.
The finding also led investigators to a new treatment target and possible therapy for the rare childhood tumor of the retina, the light-sensing tissue at the back of the eye. The study appears in the January 11 advance online edition of the scientific journal Nature.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46767-st-jude-genome-project-treatment-childhood-eye-tumor-retinoblastoma
Researchers have discovered that a subtype of leukemia characterized by a poor prognosis is fueled by mutations in pathways distinctly different from a seemingly similar leukemia associated with a much better outcome. The findings from the St. Jude Children’s Research Hospital — Washington University Pediatric Cancer Genome Project (PCGP) highlight a possible new strategy for treating patients with this more aggressive cancer.
The work provides the first details of the genetic alterations fueling a subtype of acute lymphoblastic leukemia (ALL) known as early T-cell precursor ALL (ETP-ALL). The results suggest ETP-ALL has more in common with acute myeloid leukemia (AML) than with other subtypes of ALL. The study appears in the January 12 edition of the journal Nature.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46768-st-jude-cancer-genome-sequencing-project-combat-aggressive-leukemia
Adolescents and young adults with a severe inherited immunodeficiency disorder improved following treatment with novel gene therapy developed at St. Jude Children’s Research Hospital and at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The results of this study appear today in the journal Science Translational Medicine.
The study involved five males with X-linked severe combined immunodeficiency disease (SCID-X1), also known as “Bubble Boy” disease, who were all treated at NIAID. This inherited disorder involves a mutation in the IL2RG gene that affects males and occurs in 1 of every 50,000 to 100,000 live births, leaving them with little to no immune protection.
To view the multimedia release go to:
http://www.multivu.com/players/English/7808651-st-jude-gene-therapy-results/
Symptoms improved significantly in adults with the bleeding disorder hemophilia B following a single treatment with gene therapy developed by researchers at St. Jude Children’s Research Hospital in Memphis and demonstrated to be safe in a clinical trial conducted at the University College London (UCL) in the U.K.
The findings of the six-person study mark the first proof that gene therapy can reduce disabling, painful bleeding episodes in patients with the inherited blood disorder. Results of the Phase I study appear in the December 10 online edition of the New England Journal of Medicine. The research is also scheduled to be presented December 11 at the 53rd annual meeting of the American Society of Hematology in San Diego.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46766-st-jude-children-s-research-hospital-gene-therapy-bleeding-disorder
Bruno is just as adventurous as your child, and they can watch his story unfold - just as their story does.
Aimed at children from 3-7 years of age, Gaudi Bruno is a fast-paced, exciting and interactive storybook... a beautiful introduction into nature, friendships and discovery. Unlike physical storybooks, Gaudi Bruno is fabulously interactive, allowing your child to feel as if they are exploring the world with Bruno, not just watching him.
Other features:
•Available in English, Spanish and Italian
•Over 100 animation effects, numerous controlled by the user
•Over 50 sounds that play throughoust the storybook
•Lovable characters in a lovable story
•Soundtrack featuring four original tunes
•Suitable for younger and older children, no matter of their reading ability.
•Interactive games are scattered throughout the story
Sing along with me to this cute, catchy and fun cartoon song from CLP Green Park! Plant a tree at: http://www.clpgreenpark.com from your computer or phone!
For every tree planted, CLP will donate HK$5 to green partners around Asia-Pacific. Share this wonderful cause with your friends and family! Help us plant 100,000 trees now!
Free The Children, an international charity and educational partner that focuses on delivering aid to impoverished children around the world, announced it has standardized on DocuSign, Inc. (DocuSign®) for Digital Transaction Management (DTM). With DocuSign, Free The Children keeps administrative spending to a minimum so it can ensure at least $0.90 of every dollar donated goes to supporting programs that directly benefit children in need around the world.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7312252-docusign-free-the-children-digital-transaction-management/
As entrepreneurs struggle to find desirable investments that also allow them to have an impact on the future of our country, Primrose Schools invites them to explore the benefits of opening a high-quality Primrose preschool in their communities. As the nation’s leading early education franchise company, Primrose currently has more than 350 locations in 29 states and is growing across the country.
Financial forecasters and economic developers alike point to early education as a stable investment that yields strong returns. A recent report by Child Care Aware shows that the high-quality early education industry generates a return of more than $8 for every $1 spent, meaning the returns of providing early education for children positively impact the economic development of communities and future workforce development. Last year, IBIS World reported that the industry reached a record high of $47.8 billion and is expected to continue to grow at an even faster pace than the overall child services market.
To view the multimedia release go to:
https://www.multivu.com/players/English/8014454-primrose-schools-open-your-own-school/
Asuragen Inc., a leading molecular diagnostics company, today announced results from a study demonstrating that a new molecular test called Xpansion Interpreter® can improve the determination of a woman’s risk of having a child with fragile X syndrome, the most common inherited cause of intellectual disability and autism, compared to existing risk measures. The Xpansion Interpreter Test is based on a technology breakthrough that reveals both the number and position of “interrupting” DNA sequences in the fragile X gene of the mother and more accurately estimates the likelihood that her child will have fragile X syndrome. The study will be published in the April issue of the American Journal of Medical Genetics and presented today at the 2013 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting in Phoenix, AZ.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60719-asuragen-xpansion-interpreter-xi-test-data-fragile-x-syndrome-autism
